Cardiva Medical, Inc. designs and develops vascular access management products that facilitate rapid hemostasis following diagnostic and interventional endovascular procedures. Since its founding, Cardiva has introduced a series of advanced vascular access management technologies designed to help the body heal itself.
Cardiva Medical, Inc. is a privately-held company funded by leading venture capital investors, including PTV Healthcare Capital, Canepa Healthcare LLC, Amkey Ventures LLC and Luther King Capital Management. Cardiva was presented the prestigious Frost & Sullivan Entrepreneurial Company Award, which recognizes entrepreneurial excellence in the U.S. angioplasty and vascular closure device markets.
Our latest advancement, VASCADE MVP® Venous Vascular Closure System, utilizes technology from its predecessors that have been successfully used in over 500,000 procedures to date. VASCADE MVP® was designed specifically for use in Electrophysiology procedures and was proven by Electrophysiologists in the multi-center, randomized clinical trial called AMBULATE, continuing the company’s ongoing commitment to generate compelling clinical evidence.
VASCADE MVP® receives FDA approval for 6-12F Inner Diameter (ID) multi-vessel venous vascular closure
Antegrade Study results published in Vascular Disease Management in 2018
VASCADE® receives FDA approval for use in femoral veins in 2018
VASCADE VCS approved by the FDA in 2013
VASCADE VCS approved for CE Mark in Europe in 2012
CATALYST III received 510(k) clearance in 2009
CATALYST II approved for CE Mark in Europe in 2008
CATALYST II received 510(k) clearance in 2007